VIVS
VivoSim Labs, Inc. (VIVS) 10Y Growth Potential Analysis (2026)
No material changes this month.
Revenue Growth Drivers
No five-year revenue CAGR is provided, and negative TTM sales valuation implies the current base is not yet demonstrating repeatable revenue compounding versus peers.
R&D intensity at 38.6% of revenue suggests heavy reinvestment, but the absence of proven growth conversion weakens evidence of scalable top-line expansion relative to peers.
Low net debt to EBITDA indicates balance-sheet capacity for funding growth, yet negative ROIC shows reinvestment has not translated into durable revenue productivity versus peers.
The available metrics show capital deployment without confirmed multi-year revenue acceleration, which limits confidence in compounding capacity compared with peers that already convert spend into growth.
Market Tailwinds
No filing-based evidence is provided for durable end-market expansion, so the company cannot be credited with structural demand tailwinds versus peers.
The dataset lacks segment growth, customer adoption, or geographic expansion proof, leaving market opportunity unverified relative to peers with disclosed traction.
Negative profitability and weak cash generation suggest the company is not yet benefiting from a market structure that supports efficient scaling versus peers.
Without documented demand persistence or execution evidence, market tailwinds remain speculative and therefore do not support a stronger long-term growth score.
Scalability Expansion
Capex to revenue of 20.5% and very high R&D intensity indicate reinvestment, but the absence of positive returns shows limited scalability versus peers.
Negative ROIC and negative free cash flow yield imply expansion is currently capital-consuming rather than self-funding, which constrains compounding capacity relative to peers.
The extremely negative cash conversion cycle points to working-capital inefficiency, reducing the ability to scale revenue without continued external funding versus peers.
Low leverage provides some financing flexibility, but the current operating model has not yet demonstrated repeatable expansion economics comparable with stronger peer platforms.
Constraints Limitations
Negative ROIC indicates structural value destruction at present, which materially limits the company’s ability to compound revenue efficiently versus peers.
The cash conversion cycle of 2,544 days signals severe working-capital drag, constraining scalable growth and differentiating it unfavorably from peers.
Negative interest coverage and negative free cash flow yield show limited internal funding capacity, which restricts reinvestment-led expansion relative to peers.
Missing multi-year growth history and absent segment disclosure reduce visibility into durable scaling, leaving long-term growth capacity structurally unproven versus peers.
Overall Score
VIVS shows reinvestment activity and low leverage, but the available metrics do not demonstrate repeatable revenue compounding, efficient scaling, or durable expansion versus peers.
Score Driver: Negative Roic
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on VivoSim Labs, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
